Publications

Aggarwal RR, Ryan CJ, Chan JM. Insulin-like growth factor pathway: a link between androgen deprivation therapy (ADT), insulin resistance, and disease progression in patients with prostate cancer? Urologic oncology. 2011. PMID: 21658978


Rahul Aggarwal, MD

DeNardo DG, Brennan DJ, Rexhepaj E, Ruffell B, Shiao SL, Madden SF, Gallagher WM, Wadhwani N, Keil SD, Junaid SA, Rugo HS, Hwang ES, Jirström K, West BL, Coussens LM. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer discovery. 2011. PMID: 22039576


Hope Rugo, MD

Ryan CJ, Shah S, Efstathiou E, Smith MR, Taplin ME, Bubley GJ, Logothetis CJ, Kheoh T, Kilian C, Haqq CM, Molina A, Small EJ. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clinical cancer research : an official journal of the American Association for Cancer Research. 2011. PMID: 21632851


Eric Small, MD

Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz HJ, Keaton M, Katz T, Ballal S, Rowinsky EK. A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Volume 30 of Issue 4 Investigational new drugs. 2011. PMID: 21629990


Andrew Ko, MD

Knox K, Carrigan D, Simmons G, Teque F, Zhou Y, Hackett J, Qiu X, Luk KC, Schochetman G, Knox A, Kogelnik AM, Levy JA. No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected. Science (New York, N.Y.). 2011. PMID: 21628393


Jay Levy, MD

Alhashem YN, Vinjamur DS, Basu M, Klingmüller U, Gaensler KM, Lloyd JA. Transcription factors KLF1 and KLF2 positively regulate embryonic and fetal beta-globin genes through direct promoter binding. The Journal of biological chemistry. 2011. PMID: 21610079


Karin Gaensler, MD

Bayraktar UD, Kim TK, Drews-Elger K, Benjamin C, El-Ashry D, Wieder E, Komanduri KV. Simultaneous measurement of ERα, HER2, and phosphoERK1/2 in breast cancer cell lines by flow cytometry. Breast cancer research and treatment. 2011. PMID: 21607585


Krishna Komanduri, MD

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC. Biologic markers determine both the risk and the timing of recurrence in breast cancer. Breast cancer research and treatment. 2011. PMID: 21597921


John Park, MD

Rajan N, Burn J, Langtry J, Sieber-Blum M, Lord CJ, Ashworth A. Transition from cylindroma to spiradenoma in CYLD-defective tumours is associated with reduced DKK2 expression. The Journal of pathology. 2011. PMID: 21598248


Alan Ashworth, PhD

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British journal of cancer. 2011. PMID: 21559012


Hope Rugo, MD

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British journal of cancer. 2011. PMID: 21559012


Michelle Melisko, MD

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British journal of cancer. 2011. PMID: 21559012


Pamela Munster, MD

Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, Melisko M, Ismail-Khan R, Rugo H, Moasser M, Minton SE. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. British journal of cancer. 2011. PMID: 21559012


Mark Moasser, MD

Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011. PMID: 21555686


Hope Rugo, MD

Swanson S, Ku T, Chou C. Assessment of direct ophthalmoscopy teaching using plastic canisters. Medical education. 2011. PMID: 21486343


Calvin Chou, MD

Mookherjee S, Chou CL. Bedside teaching of clinical reasoning and evidence-based physical examination. Medical education. 2011. PMID: 21486342


Calvin Chou, MD

Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. NRAS-mutant melanoma: response to chemotherapy. Archives of dermatology. 2011. PMID: 21576590


Alain Algazi, MD

Soon CW, Algazi AP, Cha EN, Webb EM, Daud AI. NRAS-mutant melanoma: response to chemotherapy. Archives of dermatology. 2011. PMID: 21576590


Adil Daud, MD

Greenberg S, Stopeck A, Rugo HS. Systemic treatment of early breast cancer--a biological perspective. Journal of surgical oncology. 2011. PMID: 21480257


Hope Rugo, MD

Carnevale J, Gropper AB, Agnew-Blais J, Mimiaga MJ, Mhango A, Bail R, Ngoma M. Knowledge base and caretaker-child communication about HIV in peri-urban schoolchildren of Lusaka, Zambia. AIDS care. 2011. PMID: 21293994


Julia Carnevale, MD